Aprea Therapeutics, Inc. Common stock (APRE) is a publicly traded Healthcare sector company. As of May 21, 2026, APRE trades at $0.91 with a market cap of $10.47M and a P/E ratio of -0.57. APRE moved +5.78% today. Year to date, APRE is +2.46%; over the trailing twelve months it is -48.58%. Its 52-week range spans $0.55 to $5.01. Analyst consensus is strong buy with an average price target of $4.07. Rallies surfaces APRE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
APRE financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. APRE recently traded at $0.91. Market cap is $10.47M. P/E ratio is -0.57. Revenue is $123.30K.
| Metric | Value |
|---|---|
| Price | $0.91 |
| Market Cap | $10.47M |
| P/E Ratio | -0.57 |
| EPS | $-1.50 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.01 |
| 52-Week Low | $0.55 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $123.30K |
| Net Income | $-11.95M |
| Gross Margin | 0.00% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $285.76K | $-12.60M | $-1.93 |
| 2024 | $1.50M | $-12.96M | $-2.35 |
| 2023 | $583.23K | $-14.29M | $-3.95 |
| 2022 | $0 | $-112.66M | $-67.99 |
3 analysts cover APRE: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $4.07.